Alnylam Pharma (ALNY) Tops Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $242.61 +6.12%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.62), $0.04 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $18.51 million versus the consensus estimate of $15.4 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
- Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
